Chronic kidney disease – a new classification and therapy

Czech version

Authors: O. Zakiyanov ^1,2; J. Vachek ^1,3; V. Tesař ¹
Authors‘ workplace: Klinika nefrologie VFN a 1. LF UK v Praze ¹; Ústav lékařské biochemie a laboratorní diagnostiky VFN a 1. LF UK v Praze ²; Farmakologický ústav 1. LF UK v Praze ³
Published in: Kardiol Rev Int Med 2014, 16(1): 49-52
Category: Internal Medicine

Overview

Chronic kidney disease (CKD) is defined as a kidney abnormality of structure or function present for more than three months, affecting health. It is a pathological condition with ever-increasing prevalence, which places an enormous burden on the health system. Early detection and appropriate treatment can slow the development of CKD and to protect the patient from reaching renal failure associated with the need for renal replacement therapy. As not only nephrologists care for patients with CKD, knowledge about this condition is essential for practising physicians including primary care physicians and specialists. This article discusses the epidemiology, risk factors, classification and treatment options and it aims to give a brief overview of current information about this serious disease.

Keywords:
chronic kidney disease – CKD – dialysis – transplantation – renal replacement therapy – RRT

Sources

1. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl 2013; 3: 1– 150.

2. US Renal Data System (USRDS). 2010 Annual Data Report: Atlas of Chronic Kidney Disease and Atlas of End‑Stage Renal Disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.

3. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all‑cause and cardiovascular mortality in general population cohorts: a collaborative meta‑analysis. Lancet 2010; 375: 2073– 2081. doi: 10.1016/ S0140– 6736(10)60674– 5.

4. Hallan S, Astor B, Romundstad S et al. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals:The HUNT II Study. Arch Intern Med 2007; 167: 2490– 2496.

5. Björk J, Jones I, Nyman U et al. Validation of the Lund‑ Malmö, Chronic Kidney Disease Epidemiology (CKD‑ EPI) and Modification of Diet in Renal Disease (MDRD) equations to estimate glomerular filtration rate in a large Swedish clinical population. Scand J Urol Nephrol 2012; 46: 212– 222. doi: 10.3109/ 00365599.2011.644859.

6. Trivedi HS, Pang MM, Campbell A et al. Slowing the progression of chronic renal failure: economic benefits and patients’ perspectives. Am J Kidney Dis 2002; 39: 721– 729.

7. Wahl P, Wolf M. FGF23 in chronic kidney disease. Adv Exp Med Biol 2012; 728: 107– 125. doi: 10.1007/ 978- 1- 4614- 0887- 1_8.

8. Tiefenthaler M, Gritsch B, Zotter K et al. Reduced costs of hospitalization at the start of hemodialysis by previous creation of an AV‑ fistula. Investigation of the Austrian system of financing data of incident patients from 1999 to October 2000 at the Landeskrankenhaus Innsbruck University Clinic. Acta Med Austriaca 2003; 30: 121– 126.

9. Upadhyay A, Earley A, Haynes SM et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154: 541– 548. doi: 10.7326/ 0003- 4819- 154- 8- 201104190– 00335.

10. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861– 869.

11. Abboud H, Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010; 362: 56– 65. doi: 10.1056/ NEJMcp0906797.

12. Locatelli F, Covic A, Eckardt KU et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348– 354. doi: 10.1093/ ndt/ gfn653.

13. Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis 2011; 18: 428– 432.